Ptc Therapeutics, Inc.

Merck Sharp + Dohme Corp.

Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Other

Ligand Pharmaceuticals, Inc.

Suresh D Babu

Tao Guo

Kurt William Saionz

Andrew William Stamford

Jared N Cumming

Corey Strickland

Ulrich Iserloh

Yusheng Wu

Thuy X H Le

William J Greenlee

Zhaoning Zhu

Brian Alexander McKittrick

Elizabeth M Smith

Lingyan Wang

John P Caldwell

Zhong-Yue Sun

Yuanzan C Ye

Rachael Catherine Hunter

Johannes H Voigt

Anuradha Bhattacharyya

Ying Huang

Young-Choon Moon

Robert D Mazzola, Jr

Nadiya Sydorenko

Jana Narasimhan

Gary Mitchell Karp

Douglas Walsh Hobbs

Matthew G Woll

Yuefei Shao

Samuel Chackalamannil

Yan Xia

Guoqing Li

Anthony A Turpoff

Jianping Pan

Zhenrong Xu

Seongwoo Hwang

Guangming Chen

Xiaoxiang Liu

Koc-Kan Ho

Xiaoyan Zhang

Nanjing Zhang

Brian F McGuinness

Aleksey I Gerasyuto

Hongyu Ren

Michelle Lee Morris

Gang Qian

Huizhong Gu

Dawit Tadesse

Jigar S Patel

Johannes H Voight

Anthony R Mazzotti

Jingqi Duo

Gaifa Lai

Jeffrey A Misiaszek

Chuanxing Qu

Scott J Barraza

Robert Mazzola

Minakshi B Jani

Lukiana Amedzo

Thuy X E Le

Wuming Yan

Jeffrey F Lowrie

Xiaoiang Liu

Md Rauful Alam

Jeffrey H Lowrie

Guizhen Dong

Ramil Y Baiazitov

William F Rencher

Michael Andrew Arnold

Christie Morrill

Rachel C Hunter

Anthony Turpoff

Tom Tuan Luong

Nicholas W Mszar

Sudipta Pal

Nathaniel T Kenton

Shankar Musunuri

Christopher H Day

James Schwing

Thuy Xe Le

Rachael C Hunter

Michelle L Morris

Jr Robert D Mazzola

Brian Mckittrick

Gang Wang

Thuy X Le

Robert D Mazzola

Nicholas Walter Mszar

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Compounds for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Heteroaryl compounds for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Compounds for treating huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Heterocyclic and heteroaryl compounds for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.  In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Methods for treating Huntington's disease

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. 

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein  and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a &#x3b2;-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Cyclic amide BACE-1 inhibitors having a benzamide substituent

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.

Heterocyclic aspartyl protease inhibitors

The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general formula I: 

Biaryl oxyacetic acid compounds

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula I are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.

Growing community of inventors

Plainsboro, NJ, United States of America

Suresh D Babu